Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2376
PUT
Alnylam Pharmaceuticals
ALNY
$29.6B
| $3.98M | ﹤0.01% |
+10,000
| New | +$4.43M |
|
2377
SK Telecom
SKM
$15.1B
| $3.97M | ﹤0.01% |
193,550
+193,206
| +56,165% | +$3.97M |
|
2378
Enerpac Tool Group
EPAC
$1.88B
| $3.97M | ﹤0.01% |
103,853
+8,675
| +9% | +$343K |
|
|
ITWO
2379
ProShares Russell 2000 High Income ETF
ITWO
$202M
| $3.97M | ﹤0.01% |
100,000
| – | – |
|
2380
Trustmark
TRMK
$2.82B
| $3.96M | ﹤0.01% |
101,787
+18,236
| +22% | +$710K |
|
2381
RLI Corp
RLI
$5.86B
| $3.96M | ﹤0.01% |
61,862
-92,998
| -60% | -$5.84M |
|
2382
Cousins Properties
CUZ
$4.95B
| $3.96M | ﹤0.01% |
153,519
-118,283
| -44% | -$3.07M |
|
2383
Vita Coco
COCO
$3.77B
| $3.94M | ﹤0.01% |
74,395
+6,755
| +10% | +$317K |
|
2384
Standard BioTools
LAB
$288M
| $3.94M | ﹤0.01% |
3,080,579
-94,055
| -3% | -$126K |
|
2385
CALL
Goodyear
GT
$1.77B
| $3.94M | ﹤0.01% |
450,000
| – | – |
|
2386
Nuvation Bio
NUVB
$2.08B
| $3.94M | ﹤0.01% |
439,272
-56,662
| -11% | -$351K |
|
2387
Vicor
VICR
$10.7B
| $3.93M | ﹤0.01% |
35,870
+1,391
| +4% | +$118K |
|
2388
CALL
Cadiz
CDZI
$284M
| $3.93M | ﹤0.01% |
700,000
| – | – |
|
2389
Martin Midstream Partners
MMLP
$91.9M
| $3.92M | ﹤0.01% |
1,500,000
| – | – |
|
2390
Atkore
ATKR
$3.17B
| $3.91M | ﹤0.01% |
61,865
+5,902
| +11% | +$385K |
|
2391
Lazard
LAZ
$4.4B
| $3.91M | ﹤0.01% |
80,483
+51,644
| +179% | +$2.58M |
|
2392
CALL
AT&T
T
$170B
| $3.91M | ﹤0.01% |
157,300
| – | – |
|
2393
First American
FAF
$7.52B
| $3.9M | ﹤0.01% |
63,515
-33,731
| -35% | -$2.12M |
|
2394
Gibraltar Industries
ROCK
$1.44B
| $3.9M | ﹤0.01% |
78,890
+9,440
| +14% | +$541K |
|
|
BAND
2395
Bandwidth Inc
BAND
$1.7B
| $3.9M | ﹤0.01% |
252,284
+8,049
| +3% | +$122K |
|
2396
Allegiant Air
ALGT
$2.34B
| $3.89M | ﹤0.01% |
45,662
-19,420
| -30% | -$1.39M |
|
2397
Tidewater
TDW
$4.65B
| $3.89M | ﹤0.01% |
77,026
+6,001
| +8% | +$317K |
|
2398
Pembina Pipeline
PBA
$28.7B
| $3.89M | ﹤0.01% |
102,197
+6,851
| +7% | +$264K |
|
2399
PUT
uniQure
QURE
$3.22B
| $3.89M | ﹤0.01% |
162,500
-27,800
| -15% | -$1.07M |
|
2400
Crescent Energy
CRGY
$4B
| $3.89M | ﹤0.01% |
463,124
+189,468
| +69% | +$1.66M |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.